HC Wainwright Reiterates “Buy” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 75.05% from the stock’s previous close.

A number of other research firms have also weighed in on TLX. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday. Finally, Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $20.50.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX traded up $0.12 during midday trading on Friday, hitting $11.43. The company’s stock had a trading volume of 364,752 shares, compared to its average volume of 221,488. Telix Pharmaceuticals has a fifty-two week low of $6.28 and a fifty-two week high of $13.11. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. The firm’s 50 day moving average is $11.33 and its 200-day moving average is $10.47.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of hedge funds have recently modified their holdings of TLX. Bank of America Corp DE grew its stake in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after buying an additional 8,423 shares during the period. XY Capital Ltd acquired a new stake in shares of Telix Pharmaceuticals in the first quarter valued at $120,000. Hennion & Walsh Asset Management Inc. acquired a new position in Telix Pharmaceuticals during the 2nd quarter worth about $1,731,000. Private Advisor Group LLC grew its position in Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after acquiring an additional 128,070 shares in the last quarter. Finally, Lazard Asset Management LLC increased its stake in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares during the period.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.